Feng Yanfei, Yang Zitong, Xu Xin
The Second Affiliated College, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Cancer Manag Res. 2022 Aug 8;14:2379-2388. doi: 10.2147/CMAR.S369175. eCollection 2022.
Mesenchymal-epithelial transition factor (c-Met) belongs to the tyrosine kinase receptor family and is overexpressed in various human cancers. Its ligand is hepatocyte growth factor (HGF), and the HGF/c-Met signaling pathway is involved in a wide range of cellular processes, including cell proliferation, migration, and metastasis. Emerging studies have indicated that c-Met expression is strongly associated with bladder cancer (BCa) development and prognosis. Therefore, c-Met is a potential therapeutic target for BCa treatment. Recently, the aberrant expression of noncoding RNAs was found to play a significant role in tumour progression. There is a close connection between c-Met and noncoding RNA. Herein, we summarized the biological function and prognostic value of c-Met in BCa, as well as its potential role as a drug target. The relation of c-Met and ncRNA was also described in the paper.
间充质上皮转化因子（c-Met）属于酪氨酸激酶受体家族，在多种人类癌症中过表达。其配体是肝细胞生长因子（HGF），HGF/c-Met信号通路参与广泛的细胞过程，包括细胞增殖、迁移和转移。新兴研究表明，c-Met表达与膀胱癌（BCa）的发生发展及预后密切相关。因此，c-Met是BCa治疗的潜在靶点。最近发现，非编码RNA的异常表达在肿瘤进展中起重要作用。c-Met与非编码RNA之间存在密切联系。在此，我们总结了c-Met在BCa中的生物学功能和预后价值，以及其作为药物靶点的潜在作用。本文还描述了c-Met与ncRNA的关系。
